2-(4-(4-Fluorobenzoyl)piperidin-1-YL)acetic acid → 2-(4-(4-Fluorobenzoyl)piperidin-1-yl)-N-neopentyl-N-((4-oxo-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-2-yl)methyl)acetamide

Participants

Reaction Steps

The title compound (17 mg) was prepared following the general procedure of Example 1 from 2-((neopentylamino)methyl)-7,8-dihydro-3H-pyrano[4,3-d]pyrimidin-4(5H)-one (50 mg, 0.20 mmol) and 2-(4-(4-fluorobenzoyl)piperidin-1-yl)acetic acid (62 mg, 0.20 mmol). 1H NMR (400 MHz, CDC3) δ 7.98 (dd, J=9.0, 5.5 Hz, 2H), 7.07-7.21 (m, 2H), 4.61 (s, 2H), 4.49 (br. s., 2H), 3.86-4.05 (m, 2H), 3.30-3.50 (m, 3H), 3.13-3.29 (m, 2H), 2.90-3.13 (m, 2H), 2.52-2.76 (m, 4H), 2.01-2.27 (m, 3H), 1.88 (d, J=3.0 Hz, 1H), 1.02 (s, 3H), 0.96 (s, 7H). HRMS calculated for C27H35FN4O4 499.2721. found (ESI, [M+H]+), 499.2738. MS m/z 499.3 (M+1), retention time=3.32 min.

Provenance & Evidence